ArticleThe Journal of clinical investigation2026

Redirection of sphingolipid metabolism drives cytoskeletal defects in SPLIS and reveals ROCK inhibition as therapy.

Adam Majcher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.